Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study on the Safety of CC312 in Treating Patients With Refractory Autoimmune Diseases

NCT06888960 is registered in ClinicalTrials.gov with CytoCares Inc as lead sponsor.

NCT NCT06888960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06888960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study on the Safety of CC312 in Treating Patients With Refractory Autoimmune Diseases
Lead sponsor
CytoCares Inc
Phase
Phase 1
Overall status
Recruiting
Start date
November 8, 2024
Completion date
November 8, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia, idiopathic inflammatory myopathy (iim), primary immune thrombocytopenia (itp), rheumatoid arthritis (ra), systemic lupus erythematosus (sle), systemic sclerosis (ssc)